Combining Opioid and Adrenergic Mechanisms for Chronic Pain

References

• . US Department of Health and Human Services, Centers for Disease Control and Prevention. Health, United States, 2011 with chartbook on trends in the health of Americans. Hyattsville, MD: National Center for Health Statistics; 2011
   Google Scholar
• . Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain. 2010;11(11):1230–1239
   PubMed Web of Science ®Google Scholar
• . National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. http://nationalpaincentre.mcmaster.ca/opioid/. Accessed September 18, 2013
   Google Scholar
• . Chou R, Fanciullo GJ, Fine PG, . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130
   PubMed Web of Science ®Google Scholar
• . Manchikanti L, Abdi S, Atluri S, ; American Society of Interventional Pain Physicians. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15( 3 suppl):S67–S116
   PubMed Web of Science ®Google Scholar
• . Smith HS, Elliott JA. Opioid-induced androgen deficiency (OPIAD). Pain Physician. 2012;15( 3 suppl):ES145–ES156
   PubMed Web of Science ®Google Scholar
• . Goldberg JS. Chronic opioid therapy and opioid tolerance: a new hypothesis. Pain Res Treat. 2013;2013:407504
   PubMedGoogle Scholar
• . Manchikanti L, Helm S 2nd, Fellows B, . Opioid epidemic in the United States. Pain Physician. 2012;15( 3 suppl):ES9–ES38
   PubMed Web of Science ®Google Scholar
• . Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59(9):1279–1298
   PubMed Web of Science ®Google Scholar
• . Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Rodriguez G, Nalamachu S, Langley P. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract. 2013;13(3):239–252
   PubMed Web of Science ®Google Scholar
• . Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134–142
   PubMed Web of Science ®Google Scholar
• . McCarberg B, Tenzer P. Complexities in the pharmacologic management of osteoarthritis pain. Curr Med Res Opin. 2013;29(5):539–548
   PubMed Web of Science ®Google Scholar
• . Nuesch E, Hauser W, Bernardy K, Barth J, Juni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis. 2013;72(6):955–962
   PubMed Web of Science ®Google Scholar
• . Tesfaye S, Vileikyte L, Rayman G, . Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629–638
   PubMed Web of Science ®Google Scholar
• . Hartrick CT, Rozek RJ. Tapentadol in pain management: a mu-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs. 2011;25(5):359–370
   PubMed Web of Science ®Google Scholar
• . Afilalo M, Etropolski MS, Kuperwasser B, . Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30(8):489–505
   PubMed Web of Science ®Google Scholar
• . Steigerwald I, Muller M, Kujawa J, Balblanc JC, Calvo-Alen J. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study. J Pain Res. 2012;5:121–138
   PubMedGoogle Scholar
• . Steigerwald I, Muller M, Davies A, . Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012;28(6):911–936
   PubMed Web of Science ®Google Scholar
• . Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther. 2009;31(3):503–513
   PubMed Web of Science ®Google Scholar
• . Lange B, Kuperwasser B, Okamoto A, . Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27(6):381–399
   PubMed Web of Science ®Google Scholar
• . Wild JE, Grond S, Kuperwasser B, . Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10(5):416–427
   PubMed Web of Science ®Google Scholar
• . Buynak R, Shapiro DY, Okamoto A, . Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo-and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11(11):1787–1804
   PubMed Web of Science ®Google Scholar
• . Schwartz S, Etropolski M, Shapiro DY, . Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151–162
   PubMed Web of Science ®Google Scholar
• . DeLemos BP, Xiang J, Benson C, . Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther. 2011;18(3):216–226
   PubMed Web of Science ®Google Scholar
• . Mongin G, Yakusevich V, Kope A, . Efficacy and safety assessment of a novel once-daily tablet formulation of tramadol: a randomised, controlled study versus twice-daily tramadol in patients with osteoarthritis of the knee. Clin Drug Investig. 2004;24(9):545–558
   PubMedGoogle Scholar
• . Vorsanger G, Xiang J, Jordan D, Farrell J. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clin Ther. 2007;29( suppl):2520–2535
   PubMedGoogle Scholar
• . Vorsanger GJ, Xiang J, Gana TJ, Pascual ML, Fleming RR. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag. 2008;4(2):87–97
   PubMedGoogle Scholar
• . Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol. 2000;27(3):772–778
   PubMed Web of Science ®Google Scholar
• . Muller FO, Odendaal CL, Muller FR, Raubenheimer J, Middle MV, Kummer M. Comparison of the efficacy and tolerability of a paracetamol/codeine fixed-dose combination with tramadol in patients with refractory chronic back pain. Arzneimittelforschung. 1998;48(6):675–679
   PubMed Web of Science ®Google Scholar
• . Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol. 2009;7(4):331–336
   PubMed Web of Science ®Google Scholar
• . Raffa RB, Tallarida RJ, Taylor R Jr, Pergolizzi JV Jr. Fixed-dose combinations for emerging treatment of pain. Expert Opin Pharmacother. 2012;13(9):1261–1270
   PubMed Web of Science ®Google Scholar
• . Zhang W, Nuki G, Moskowitz RW, . OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18(4):476–499
   PubMed Web of Science ®Google Scholar
• . Noble M, Treadwell JR, Tregear SJ, . Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;(1):CD006605
   Google Scholar
• . Raja SN, Haythornthwaite JA, Pappagallo M, . Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59(7):1015–1021
   PubMed Web of Science ®Google Scholar
• . Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60(6):927–934
   PubMed Web of Science ®Google Scholar
• . Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105(1–2):71–78
   PubMed Web of Science ®Google Scholar
• . Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223–1232
   PubMed Web of Science ®Google Scholar
• . Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008;12(6):804–813
   PubMed Web of Science ®Google Scholar
• . Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med. 2003;17(7):576–587
   PubMedGoogle Scholar
• . Eisenberg E, McNicol ED, Carr DB. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain. 2006;10(8):667–676
   PubMedGoogle Scholar
• . Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA. 2005;293(24):3043–3052
   PubMed Web of Science ®Google Scholar
• . Smith HS. Opioids and neuropathic pain. Pain Physician. 2012;15( 3 suppl):ES93–ES110
   PubMed Web of Science ®Google Scholar
• . Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012;7:CD008943
   PubMed Web of Science ®Google Scholar
• . Attal N, Cruccu G, Baron R, . EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–e88
   PubMed Web of Science ®Google Scholar
• . Dworkin RH, O'Connor AB, Backonja M, . Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–251
   PubMed Web of Science ®Google Scholar
• . Skljarevski V, Ossanna M, Liu-Seifert H, . A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol. 2009;16(9):1041–1048
   PubMed Web of Science ®Google Scholar
• . Skljarevski V, Desaiah D, Liu-Seifert H, . Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976). 2010;35(13):E578–E585
   PubMed Web of Science ®Google Scholar
• . Skljarevski V, Zhang S, Chappell AS, Walker DJ, Murray I, Backonja M. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Med. 2010;11(5):648–657
   PubMed Web of Science ®Google Scholar
• . Skljarevski V, Zhang S, Desaiah D, . Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain. 2010;11(12):1282–1290
   PubMed Web of Science ®Google Scholar
• . Wernicke JF, Pritchett YL, D'Souza DN, . A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411–1420
   PubMed Web of Science ®Google Scholar
• . Raskin J, Pritchett YL, Wang F, . A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6(5):346–356
   PubMed Web of Science ®Google Scholar
• . Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1–2):109–118
   PubMed Web of Science ®Google Scholar
• . Kajdasz DK, Iyengar S, Desaiah D, . Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007;29( suppl):2536–2546
   PubMed Web of Science ®Google Scholar
• . Russell IJ, Mease PJ, Smith TR, . Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432–444
   PubMed Web of Science ®Google Scholar
• . Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2010;37(12):2578–2586
   PubMed Web of Science ®Google Scholar
• . Arnold LM, Lu Y, Crofford LJ, . A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974–2984
   PubMed Web of Science ®Google Scholar
• . Chappell AS, Desaiah D, Liu-Seifert H, . A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract. 2011;11(1):33–41
   PubMed Web of Science ®Google Scholar
• . Chappell AS, Ossanna MJ, Liu-Seifert H, . Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain. 2009;146(3):253–260
   PubMed Web of Science ®Google Scholar
• . Cymbalta (duloxetine hydrochloride). Full Prescribing Information [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011
   Google Scholar
• . Karp JF, Weiner DK, Dew MA, Begley A, Miller MD, Reynolds CF 3rd. Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study. Int J Geriatr Psychiatry. 2010;25(6):633–642
   PubMedGoogle Scholar
• . Wattiez AS, Libert F, Privat AM, . Evidence for a differential opioidergic involvement in the analgesic effect of antidepressants: prediction for efficacy in animal models of neuropathic pain? Br J Pharmacol. 2011;163(4):792–803
   PubMed Web of Science ®Google Scholar
• . Mixcoatl-Zecuatl T, Jolivalt CG. A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy. Br J Pharmacol. 2011;164(1):159–169
   PubMedGoogle Scholar
• . Yucel A, Ozyalcin S, Koknel Talu G, . The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain. 2005;9(4):407–416
   PubMed Web of Science ®Google Scholar
• . Sullivan M, Bentley S, Fan MY, Gardner G. A single-blind placebo run-in study of venlafaxine XR for activity-limiting osteoarthritis pain. Pain Med. 2009;10(5):806–812
   PubMed Web of Science ®Google Scholar
• . Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(9):2745–2756
   PubMedGoogle Scholar
• . Kogel B, De Vry J, Tzschentke TM, Christoph T. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (mu-opioid receptor) knockout mice. Neurosci Lett. 2011;491(2):104–107
   PubMed Web of Science ®Google Scholar
• . Christoph T, De Vry J, Tzschentke TM. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Lett. 2010;470(2):91–94
   PubMedGoogle Scholar
• . Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther. 1992;260(1):275–285
   PubMed Web of Science ®Google Scholar
• . Tzschentke TM, Folgering JH, Flik G, De Vry J. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. Neurosci Lett. 2012;507(2): 151–155
   PubMed Web of Science ®Google Scholar
• . Bee TK, Fabian TC. History of the department of surgery at the University of Tennessee Health Science Center at Memphis. Am Surg. 2011;77(2):139–143
   PubMedGoogle Scholar
• . Raffa RB, Buschmann H, Christoph T, . Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012;13(10):1437–1449
   PubMed Web of Science ®Google Scholar
• . Pergolizzi J, Alegre C, Blake D, . Current considerations for the treatment of severe chronic pain: the potential for tapentadol. Pain Pract. 2012;12(4):290–306
   PubMedGoogle Scholar
• . Schroder W, Tzschentke TM, Terlinden R, . Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther. 2011;337(1):312–320
   PubMed Web of Science ®Google Scholar
• . Schiene K, De Vry J, Tzschentke TM. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain. J Pharmacol Exp Ther. 2011;339(2):537–544
   PubMed Web of Science ®Google Scholar
• . Arbaiza D, Vidal O. Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study. Clin Drug Investig. 2007;27(1):75–83
   PubMed Web of Science ®Google Scholar
• . Norrbrink C, Lundeberg T. Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial. Clin J Pain. 2009;25(3):177–184
   PubMed Web of Science ®Google Scholar
• . Nucynta (tapentadol). Full Prescribing Information [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2012
   Google Scholar
• . Lerner D, Chang H, Rogers WH, . Imputing at-work productivity loss using results of a randomized controlled trial comparing tapentadol extended release and oxycodone controlled release for osteoarthritis pain. J Occup Environ Med. 2012;54(8):933–938
   PubMedGoogle Scholar
• . Nucynta ER (tapentadol). Full Prescribing Information [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2012
   Google Scholar
• . Ultram ER (tramadol hydrochloride). Full Prescribing Information [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2009
   Google Scholar
• . Ultram (tramadol hydrochloride tablets). Full Prescribing Information [package insert]. Raritan, NJ: Ortho-McNeil; 2004
   Google Scholar
• . Vallejo R, Barkin RL, Wang VC. Pharmacology of opioids in the treatment of chronic pain syndromes. Pain Physician. 2011;14(4):E343–E360
   PubMed Web of Science ®Google Scholar
• . Raffa RB, Pergolizzi JV Jr, Tallarida RJ. The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain. 2010;11(8):701–709
   PubMed Web of Science ®Google Scholar
• . Christoph T, De Vry J, Schiene K, Tallarida RJ, Tzschentke TM. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Eur J Pharmacol. 2011;666(1–3):72–79
   PubMed Web of Science ®Google Scholar
• . Codd EE, Martinez RP, Molino L, Rogers KE, Stone DJ, Tallarida RJ. Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia. Pain. 2008;134(3):254–262
   PubMedGoogle Scholar
• . Tallarida RJ. Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther. 2012;342(1):2–8
   PubMed Web of Science ®Google Scholar
• . Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30(7):1206–1227
   PubMed Web of Science ®Google Scholar
• . Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263–1270
   PubMed Web of Science ®Google Scholar
• . Rastogi R, Swarm RA, Patel TA. Case scenario: opioid association with serotonin syndrome: implications to the practitioners. Anesthesiology. 2011;115(6):1291–1298
   PubMedGoogle Scholar
• . Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Pract. 2011;11(3):230–239
   PubMed Web of Science ®Google Scholar
• . Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Ben-Joseph R, Ohsfeldt R, Summers KH. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract. 2012;12(1):45–56
   PubMed Web of Science ®Google Scholar
• . Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–624
   PubMed Web of Science ®Google Scholar
• . Peniston JH, Hu X, Potts SL, Wieman MS, Turk DC. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release. Postgrad Med. 2012;124(2):114–122
   PubMed Web of Science ®Google Scholar
• . Brett V, Sikes C, Xiang J, Oh C, Biondi D. Post hoc analysis of pooled safety data from 11 phase 3 clinical trials to identify potential pharmacodynamic drug interactions between tapentadol and SSRIs/SNRIs. Paper presented at: PAINWeek; September 5–8, 2012; Las Vegas, NV
   Google Scholar
• . Argoff CE, Stanos SP, Wieman MS. Validity testing of patient objections to acceptance of tamper-resistant opioid formulations. J Pain Res. 2013;6:367–373
   PubMed Web of Science ®Google Scholar
• . Ziegler D, Pritchett YL, Wang F, . Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007;30(3):664–669
   PubMed Web of Science ®Google Scholar
• . Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011;34(4):818–822
   PubMed Web of Science ®Google Scholar
• . Rowbotham MC, Arslanian A, Nothaft W, . Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain. Pain. 2012;153(4):862–868
   PubMed Web of Science ®Google Scholar
• . Arnold LM, Rosen A, Pritchett YL, . A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1–3):5–15
   PubMed Web of Science ®Google Scholar
• . Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clin J Pain. 2012;28(9):775–781
   PubMed Web of Science ®Google Scholar
• . Gao Y, Ning G, Jia WP, . Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J (Engl). 2010;123(22):3184–3192
   PubMed Web of Science ®Google Scholar
• . Mease PJ, Spaeth M, Clauw DJ, . Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res (Hoboken). 2011;63(6):821–826
   PubMedGoogle Scholar
• . Mease PJ, Russell IJ, Kajdasz DK, . Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum. 2010;39(6):454–464
   PubMed Web of Science ®Google Scholar
• . Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006;7(5):373–385
   PubMed Web of Science ®Google Scholar
• . Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain. 2009;25(5):365–375
   PubMedGoogle Scholar
• . Geisser ME, Clauw DJ, Strand V, Gendreau RM, Palmer R, Williams DA. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain. 2010;149(2):373–378
   PubMed Web of Science ®Google Scholar
• . Saxe PA, Arnold LM, Palmer RH, Gendreau RM, Chen W. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Curr Med Res Opin. 2012;28(5):815–821
   PubMed Web of Science ®Google Scholar
• . Branco JC, Zachrisson O, Perrot S, Mainguy Y. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol. 2010;37(4):851–859
   PubMedGoogle Scholar
• . Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19( suppl 1):S27–S35
   PubMed Web of Science ®Google Scholar
• . Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract. 2011;11(2):120–131
   PubMed Web of Science ®Google Scholar
• . Mease PJ, Clauw DJ, Gendreau RM, . The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(2):398–409
   PubMed Web of Science ®Google Scholar
• . Branco JC, Cherin P, Montagne A, Bouroubi A. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol. 2011;38(7):1403–1412
   PubMedGoogle Scholar
• . Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697–706
   PubMed Web of Science ®Google Scholar
• . Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45(2):144–152
   PubMed Web of Science ®Google Scholar
• . Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(12):2361–2372
   PubMed Web of Science ®Google Scholar
• . Mazza M, Mazza O, Pazzaglia C, Padua L, Mazza S. Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. Expert Opin Pharmacother. 2010;11(7):1049–1052
   PubMed Web of Science ®Google Scholar
• . Skljarevski V, Desaiah D, Zhang Q, . Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev. 2009;25(7):623–631
   PubMedGoogle Scholar
• . Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001;98(5 Pt 1):737–744
   PubMedGoogle Scholar
• . Wise TN, Wiltse CG, Iosifescu DV, Sheridan M, Xu JY, Raskin J. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract. 2007;61(8):1283–1293
   PubMedGoogle Scholar
• . Pangallo BA, Zhang Q, Desaiah D, Perahia DG, Detke MJ, Kennedy SH. Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. Curr Med Res Opin. 2010;26(11):2643–2651
   PubMed Web of Science ®Google Scholar
• . Etropolski MS, Okamoto A, Shapiro DY, Rauschkolb C. Dose conversion between tapentadol immediate and extended release for low back pain. Pain Physician. 2010;13(1):61–70
   PubMed Web of Science ®Google Scholar
• . Mariconti P, Collini R. Tramadol SR in arthrosic and neuropathic pain. Minerva Anestesiol. 2008;74(3):63–68
   PubMedGoogle Scholar
• . Sindrup SH, Konder R, Lehmann R, . Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy. Eur J Pain. 2012;16(6):849–859
   PubMed Web of Science ®Google Scholar
• . Freeman R, Raskin P, Hewitt DJ, . Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007;23(1):147–161
   PubMed Web of Science ®Google Scholar
• . Butrans Transdermal System (buprenorphine). Full Prescribing Information [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010
   Google Scholar
• . Duragesic (fentanyl transdermal system). Full Prescribing Information [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2012
   Google Scholar
• . Exalgo (hydromorphone HCl). Full Prescribing Information [package insert]. Hazelwood, MO: Mallinckrodt Pharmaceuticals, Inc; 2012
   Google Scholar
• . Methadone (methadone hydrochloride). Full Prescribing Information [package insert]. Columbus, OH: Roxane Laboratories, Inc; 2012
   Google Scholar
• . Oramorph SR (morphine sulfate). Full Prescribing Information [package insert]. Newport, KY: Xanodyne Pharmaceuticals, Inc; 2007
   Google Scholar
• . Opana ER (oxymorphone hydrochloride). Full Prescribing Information [package insert]. Malvern, PA: Endo Pharmaceuticals; 2013
   Google Scholar
• . Effexor XR (venlafaxine HCl extended-release capsules). Full Prescribing Information [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2012
   Google Scholar
• . Savella (milnacipran HCl tablets). Full Prescribing Information [package insert]. Earth City, MO: Forest Pharmaceuticals, Inc; 2013
   Google Scholar
• . AllDrugs.info. Tapentadol. http://alldrugs.info/tapentadol. Accessed November 18, 2013
   Google Scholar